Severe Refractory Scarring Alopecia Associated With Combinational Use of Ficlatuzumab (AV-299) and Gefitinib

    May 2013 in “ Journal of Clinical Oncology ”
    Yi‐Hsien Shih, Pin-Chun Chen, Chia‐Yu Chu
    Studysummary Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on ascopubs.org →
    Discuss this study in the Community →

    Research cited in this study 5

    1. Scarring Alopecia Associated With the Epidermal Growth Factor Receptor Inhibitor Erlotinib Journal of the American Academy of Dermatology · 2011
    2. Folliculitis Decalvans Associated with Erlotinib Clinical and Experimental Dermatology · 2010
    3. A Case Report of Inflammatory Nonscarring Alopecia Associated with the Epidermal Growth Factor Receptor Inhibitor Erlotinib Journal of Cutaneous Pathology · 2009
    4. Nonscarring Inflammatory Alopecia Associated With the Epidermal Growth Factor Receptor Inhibitor Gefitinib Journal of the American Academy of Dermatology · 2006
    5. Two Distinct Signaling Pathways in Hair Cycle Induction: Stat3-Dependent and Independent Pathways Proceedings of the National Academy of Sciences of the United States of America · 2000